Susquehanna International Group’s Black Diamond Therapeutics BDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$168K Sell
78,858
-25,866
-25% -$61.5K ﹤0.01% 11877
2025
Q4
$254K Buy
+104,724
New +$371K ﹤0.01% 10331
2025
Q3
Sell
-120,073
Closed -$351K 12389
2025
Q2
$298K Buy
120,073
+42,548
+55% +$82K ﹤0.01% 10355
2025
Q1
$120K Buy
77,525
+42,853
+124% +$89.8K ﹤0.01% 11409
2024
Q4
$74.2K Buy
+34,672
New +$99.4K ﹤0.01% 11511
2024
Q3
Sell
-25,266
Closed -$137K 11976
2024
Q2
$118K Sell
25,266
-398,657
-94% -$2.14M ﹤0.01% 10898
2024
Q1
$2.15M Buy
423,923
+203,613
+92% +$821K ﹤0.01% 5164
2023
Q4
$619K Buy
220,310
+8,991
+4% +$21.1K ﹤0.01% 8143
2023
Q3
$606K Buy
211,319
+159,833
+310% +$589K ﹤0.01% 7774
2023
Q2
$260K Sell
51,486
-56,247
-52% -$115K ﹤0.01% 9730
2023
Q1
$204K Buy
107,733
+41,919
+64% +$96.3K ﹤0.01% 10553
2022
Q4
$118K Sell
65,814
-23,782
-27% -$42.8K ﹤0.01% 10778
2022
Q3
$151K Sell
89,596
-40,805
-31% -$126K ﹤0.01% 11225
2022
Q2
$321K Buy
130,401
+109,144
+513% +$254K ﹤0.01% 9398
2022
Q1
$59K Sell
21,257
-17,180
-45% -$62.7K ﹤0.01% 12230
2021
Q4
$205K Sell
38,437
-23,029
-37% -$161K ﹤0.01% 11386
2021
Q3
$520K Sell
61,466
-49,083
-44% -$485K ﹤0.01% 9291
2021
Q2
$1.35M Buy
110,549
+76,219
+222% +$1.51M ﹤0.01% 6937
2021
Q1
$833K Buy
34,330
+24,826
+261% +$670K ﹤0.01% 8199
2020
Q4
$305K Buy
+9,504
New +$312K ﹤0.01% 9215

Other funds holding BDTX

Susquehanna International Group's BDTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Black Diamond Therapeutics (BDTX) stake by 25% in Q1 2026, selling an estimated $61.5K and leaving 78,858 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #11877.

Susquehanna International Group first reported a position in BDTX in Q4 2020 and has held it in 20 quarters since. The position peaked at $2.15M in Q1 2024. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Susquehanna International Group held 78,858 shares of Black Diamond Therapeutics worth $168K as of Q1 2026.
  • Susquehanna International Group sold 25,866 Black Diamond Therapeutics shares in Q1 2026, an estimated $61.5K.
  • Black Diamond Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11877 holding.
  • Susquehanna International Group first reported a position in Black Diamond Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Susquehanna International Group's Black Diamond Therapeutics position peaked at $2.15M in Q1 2024.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.